Significant rebound for the first time in 6 days. It has been announced that the Line-1 inhibitor “OBP-601 (TPN-101),” which our company has signed a worldwide license agreement with TransPoson, has been designated as a fast track against progressive supranuclear palsy (PSP) by the U.S. Food and Drug Administration (FDA). Cooperation with the FDA will be strengthened by designation, and there is a possibility that drug development will be accelerated. As a result of Phase 2 clinical trials against PSP, OBP-601 suppresses inflammation of cranial nerves as a LINE-1 inhibitor and suppresses nerve damage.
オンコリス---大幅に6日ぶり反発、米FDAがLINE-1阻害剤「OBP-601」をファストトラック指定
Oncolis---major backlash for the first time in 6 days, US FDA designates LINE-1 inhibitor “OBP-601” as a fast track
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.